Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Charité Artificial Disc: insertion technique.

Henry E Aryan1, Frank L Acosta, Christopher P Ames

  • 1Department of Neurological Surgery, University of California, San Francisco, CA 94143-0350, USA.

Neurosurgery Clinics of North America
|December 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-specific Cervical Deformity Corrections With Consideration of Associated Risk: Establishment of Risk Benefit Thresholds for Invasiveness Based on Deformity and Frailty Severity.

Clinical spine surgery·2023
Same author

Economic burden of nonoperative treatment of adult spinal deformity.

Journal of neurosurgery. Spine·2023
Same author

The ISSG-AO Complication Intervention Score, but Not Major/Minor Designation, is Correlated With Length of Stay Following Adult Spinal Deformity Surgery.

Global spine journal·2023
Same author

Functional Alignment Within the Fusion in Adult Spinal Deformity (ASD) Improves Outcomes and Minimizes Mechanical Failures.

Spine·2023
Same author

Are We Focused on the Wrong Early Postoperative Quality Metrics? Optimal Realignment Outweighs Perioperative Risk in Adult Spinal Deformity Surgery.

Journal of clinical medicine·2023
Same author

Are we improving in the optimization of surgery for high-risk adult cervical spine deformity patients over time?

Journal of neurosurgery. Spine·2023
Same journal

Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Spinal Cord Deformities Associated with Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Radiation Therapy for Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Treatment Strategies of Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Vascular Lesions of the Spinal Cord: Arteriovenous and Cavernous Malformations.

Neurosurgery clinics of North America·2026
Same journal

Hemangioblastomas of the Spinal Cord.

Neurosurgery clinics of North America·2026
See all related articles

This article reviews the clinical history and surgical application of the Charité Artificial Disc, a device designed to replace damaged lumbar discs while maintaining spinal movement. It highlights its status as the first FDA-approved motion-preserving implant for treating degenerative disc disease in the lower spine.

Area of Science:

  • Orthopedic surgery and Charité Artificial Disc clinical outcomes
  • Spinal biomechanics and medical device innovation

Background:

Current surgical options for lumbar degenerative disc disease often involve spinal fusion, which restricts natural movement. This limitation creates a need for motion-preserving alternatives that restore normal spinal function. The Charité Artificial Disc emerged as a pioneering solution to address these biomechanical challenges. Prior research has shown that traditional fusion techniques may lead to adjacent segment degeneration over time. That uncertainty drove the development of artificial disc technology to improve long-term patient outcomes. No prior work had resolved the debate regarding the safety and efficacy of early lumbar arthroplasty devices. This gap motivated a comprehensive look at the historical data surrounding this specific implant. The device remains a significant milestone in the evolution of spinal surgery.

Purpose Of The Study:

The aim of this study is to provide a comprehensive review of the Charité Artificial Disc and its clinical application. This work addresses the need for a clear understanding of the device's historical and regulatory background. The researchers seek to clarify why this implant is considered a pioneer in motion-preserving spinal surgery. This investigation explores the specific indications for treating single-level lumbar degenerative disc disease. The authors intend to highlight the importance of long-term clinical data in validating medical devices. This study examines the transition from traditional fusion techniques to artificial disc replacement. The motivation stems from the necessity to document the extensive experience gained since the device's introduction in 1987. This review serves to inform clinicians about the unique status of this technology within the orthopedic field.

Keywords:
spinal surgerydegenerative disc diseaseorthopedic implantsvertebral motion

Frequently Asked Questions

The device functions by replacing a damaged lumbar disc with an artificial implant, which preserves natural motion at the affected spinal level. This approach contrasts with traditional fusion methods that permanently immobilize the vertebral segments.

The Charité Artificial Disc represents the specific technology discussed. It differs from other spinal implants by being the first US Food and Drug Administration-approved motion-preserving device for the lumbar region.

The L4 to S1 lumbar levels are necessary for this procedure. The researchers propose that targeting these specific segments allows for effective treatment of single-level degenerative disc disease.

Clinical history data serves as the primary evidence type. The authors use these records to validate the device's long-term safety profile compared to newer, less-tested implants.

Related Experiment Videos

Main Methods:

Review Approach involves a systematic analysis of historical clinical data and preclinical documentation. The authors evaluate the device's performance based on global implantation records starting from 1987. This methodology focuses on synthesizing evidence regarding the implant's regulatory approval status. Researchers examine the specific indications for single-level degenerative disc disease treatment. The study design utilizes a retrospective look at the evolution of motion-preserving spinal technologies. Investigators compare the Charité device against other available artificial discs to establish its unique standing. The team assesses the validity of the implant through its extensive longitudinal history. This approach ensures a thorough understanding of the device's role in modern orthopedic practice.

Main Results:

Key Findings From the Literature indicate that the Charité Artificial Disc is the first motion-preserving technology for the lumbar spine. The device holds the distinction of being the first US Food and Drug Administration-approved implant for single-level lumbar degenerative disc disease. Clinical application spans the L4 to S1 vertebral segments. Global usage includes thousands of successful implantations since the year 1987. The literature confirms this device possesses the longest clinical experience of any artificial disc currently available. No other similar technology provides the same depth of preclinical and clinical validation. These results highlight the device's established position within the field of spinal surgery. The data confirms that its historical record remains unmatched by competing artificial disc systems.

Conclusions:

Synthesis and Implications suggest the Charité Artificial Disc provides a unique, motion-preserving option for lumbar spine treatment. The authors emphasize its role as the inaugural FDA-approved device for single-level degenerative disc disease. Clinical evidence supports its use across the L4 to S1 lumbar segments. Long-term data from global implantations since 1987 validate the device's historical significance. No other artificial disc currently possesses a comparable depth of preclinical and clinical documentation. These findings imply that the device serves as a benchmark for evaluating newer spinal technologies. The authors conclude that its extensive track record remains a defining feature of its clinical profile. Future assessments should continue to weigh this historical validation against modern surgical advancements.

The measurement of success involves tracking patient outcomes across thousands of global implantations. This phenomenon demonstrates the device's longevity compared to other artificial discs lacking such extensive history.

The authors imply that the extensive clinical history of the Charité Artificial Disc sets a standard for validation. They suggest this history distinguishes it from other artificial discs currently available.